Literature DB >> 20145132

miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma.

Chung-Ji Liu1, Meng-Miao Tsai, Pei-Shih Hung, Shou-Yen Kao, Tsung-Yun Liu, Kou-Juey Wu, Shih-Hwa Chiou, Shu-Chun Lin, Kuo-Wei Chang.   

Abstract

MicroRNAs (miRNA) are endogenously expressed noncoding RNAs with important biological and pathological functions that are yet to be fully defined. This study investigated alterations in miRNA expression in head and neck squamous cell carcinoma (HNSCC), the incidence of which is rising throughout the world. Initial screening and subsequent analysis identified a panel of aberrantly expressed miRNAs in HNSCC tissues, with miR-31 among the most markedly upregulated. Ectopic expression of miR-31 increased the oncogenic potential of HNSCC cells under normoxic conditions in cell culture or tumor xenografts. Conversely, blocking miR-31 expression reduced the growth of tumor xenografts. The in silico analysis suggested that miR-31 may target the 3' untranslated region (UTR) of factor-inhibiting hypoxia-inducible factor (FIH), a hypoxia-inducible factor (HIF) regulatory factor that inhibits the ability of HIF to act as a transcriptional regulator under normoxic conditions. In support of this likelihood, miR-31 expression repressed FIH expression and mutations within the predictive miR-31 target site in the FIH 3' UTR abrogated FIH repression. Furthermore, miR-31 expression increased HIF transactivation activity. We found that FIH suppressed oncogenic phenotypes under normoxic conditions and that this activity was abrogated by functional mutations. Lastly, increased miR-31 expression was correlated with decreased levels of FIH in tumor tissues. Our findings suggest that miR-31 contributes to the development of HNSCC by impeding FIH to activate HIF under normoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145132     DOI: 10.1158/0008-5472.CAN-09-2291

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  133 in total

1.  Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer.

Authors:  Brock C Christensen; Michele Avissar-Whiting; Lauren G Ouellet; Rondi A Butler; Heather H Nelson; Michael D McClean; Carmen J Marsit; Karl T Kelsey
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 2.  Involvement of microRNAs in lung cancer biology and therapy.

Authors:  Xi Liu; Lorenzo F Sempere; Yongli Guo; Murray Korc; Sakari Kauppinen; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Transl Res       Date:  2011-02-04       Impact factor: 7.012

Review 3.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

4.  MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.

Authors:  Anand Singh; Nisan Bhattacharyya; Abhishek Srivastava; Nathanael Pruett; R Taylor Ripley; David S Schrump; Chuong D Hoang
Journal:  Mol Ther       Date:  2019-06-04       Impact factor: 11.454

5.  MicroRNA-31 targets FIH-1 to positively regulate corneal epithelial glycogen metabolism.

Authors:  Han Peng; Robert B Hamanaka; Julia Katsnelson; Liang-Liang Hao; Wending Yang; Navdeep S Chandel; Robert M Lavker
Journal:  FASEB J       Date:  2012-04-24       Impact factor: 5.191

6.  The cellular response to hypoxia: tuning the system with microRNAs.

Authors:  Joseph Loscalzo
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

7.  Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer.

Authors:  Lai Xu; Joseph Ziegelbauer; Rong Wang; Wells W Wu; Rong-Fong Shen; Hartmut Juhl; Yaqin Zhang; Amy Rosenberg
Journal:  Clin Cancer Res       Date:  2015-09-18       Impact factor: 12.531

8.  MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1).

Authors:  Defang Sun; Feng Yu; Yutao Ma; Ran Zhao; Xi Chen; Jie Zhu; Chen-Yu Zhang; Jiangning Chen; Junfeng Zhang
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

9.  MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells.

Authors:  Zhiwei Zhong; Zhuo Dong; Lihua Yang; Xiaoqiang Chen; Zhaohui Gong
Journal:  Tumour Biol       Date:  2013-03-29

Review 10.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.